AutoCyte is hoping that its acquisition of NeoPath, a stock-swap transaction valued at over $100 mil., will result in a 50% share of the U.S. Pap smear market.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.
The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.
16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.
